NCT02985749

A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

A Pilot Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 12 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This study is an 8-week pilot trial with oxytocin nasal spray (Syntocinon) as a treatment for social impairment in children and adults with high functioning autism spectrum disorders (ASD). The investigators hypothesize that oxytocin will be safe, tolerable, and effective in improving social deficits in individuals with ASD.

Conditions

• Autism Spectrum Disorder
• Pervasive Developmental Disorder
• ASD
• PDD

Interventions

Type	Name	Description
DRUG	Intranasal Oxytocin	This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).

Timeline

• Start date: 2017-10-09
• Primary completion: 2019-01-09
• Completion: 2019-01-09
• First posted: 2016-12-07
• Last updated: 2024-07-01
• Results posted: 2023-08-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study